Yazar "Artac, Mehmet" seçeneğine göre listele
Listeleniyor 1 - 13 / 13
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The acute effect of tropisetron on ECG parameters in cancer patients(SPRINGER, 2008) Yavas, Ozlem; Yazici, Mehmet; Eren, Onder; Boruban, Cem; Artac, Mehmet; Genc, MineObjectives The 5-hydroxytryptamine 3 receptor antagonists, including tropisetron, ondansetron, granisetron, and dolasetron are agents used effectively for supportive care. They are used for the prevention and treatment of chemotherapy and radiotherapy-induced emesis. Despite their overall excellent safety profile, some electrocardiographic changes related to heart rate and repolarization were reported. Ondansetron, granisetron, and dolasetron were studied on this manner. But to our knowledge, there is no information about the cardiac side effects of tropisetron. In this study, we aimed to determine the acute effects of tropisetron on ECG parameters related to repolarization, heart rate, and systemic blood pressure. Materials and methods Fifty-five cancer patients who received tropisetron for the prevention of acute chemotherapy-induced nausea and vomiting were enrolled into this single center, prospective study. Standard 12-lead ECG recordings were performed at baseline and 30 min after tropisetron (5 mg given over 1 min IV bolus) administration. P wave durations and corrected QT intervals were measured; P wave dispersion and QTc dispersion were calculated. Results In comparison with baseline, mean heart rate significantly decreased 30 min after administration of tropisetron. Tropisetron did not result in a significant change in P wave duration, corrected QT interval, P dispersion, and QTc dispersion. Conclusion In this study, tropisetron did not show any ventricular and atrial arrhythmogenic effect because of repolarization abnormalities. Only it may cause a slight decrease in heart rate.Öğe Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience(HUMANA PRESS INC, 2009) Eren, Orhan Onder; Artac, Mehmet; Boruban, Melih Cem; Yavas, Ozlem; Arslan, Ugur; Basaranoglu, MetinHepatitis B reactivation due to chemotherapy is a cause of serious morbidity and mortality in some of the patients with cancer. In this study, we retrospectively assessed the prevalence of hepatitis B reactivation among the patients undergoing cytotoxic chemotherapy. We investigated efficacy of lamivudine prophylaxis against hepatitis B reactivation as well.Öğe Correlation of Serum Leptin Level and Waist-to-hip Ratio (WHR) With Overall Survival of Patients With Metastatic Breast Cancer (MBC) Treated With Aromatase Inhibitors (AIs).(Amer Soc Clinical Oncology, 2013) Artac, Mehmet; Bozcuk, Hakan; Kıyıcı, Aysel; Eren, Orhan Önder; Boruban, Melih Cem; Özdoğan, MustafaIntroduction Our objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Methods Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Results Median age was 51 years (range 28–75). Median leptin level was 19400 pg/ml (1970–91900) and estradiol level 29.6 pg/ml (4.0–181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was C19400 pg/ml (HR = 0.38; 95% CI: 0.16–0.91). Conclusions This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.Öğe The debate about maintenance is not over in small-cell lung cancer(AMER SOC CLINICAL ONCOLOGY, 2007) Artac, Mehmet; Bozcuk, Hakan[Abstract not Available]Öğe Does obesity change the effect of aromatase inhibitors (AIs) on estradiol, leptin, insulin, and IGF-1 serum levels in breast cancer patients?(AMER SOC CLINICAL ONCOLOGY, 2012) Artac, Mehmet; Askin, Dudu; Kiyici, Aysel; Eren, Onder Orhan; Oncel, Mufide; Boruban, Melih Cem; Bozcuk, Hakan Sat[Abstract not Available]Öğe The effects of trastuzumab, paclitaxel, and carboplatin on HER2-positive cancer stem cells that are isolated from primary breast cancer cultures: a preliminary report(AMER ASSOC CANCER RESEARCH, 2015) Artac, Mehmet; Kayadibi, Gozde; Ceylan, Ayca; Kars, Meltem Demirel; Artac, Hasibe; Cakir, Murat; Boruban, Cem[Abstract not Available]Öğe Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.(AMER SOC CLINICAL ONCOLOGY, 2014) Uncu, Dogan; Bayoglu, Ibrahim Vedat; Arslan, Ulku Yalcintas; Kucukoner, Mehmet; Artac, Mehmet; Koca, Dogan; Oguz, Arzu[Abstract not Available]Öğe Frequency of Cytochrome 450 (CYP2C9 and CYP2C19) Genetic Polimorphisms in Patients with Colorectal Carsinoma(AKAD DOKTORLAR YAYINEVI, 2009) Buyukdogan, Murat; Boruban, M. Cem; Artac, Mehmet; Demirel, SennurColorectal cancers are important health problems particularly in developed countries, are multifactorial diseases developing by the effects of both genetic and environmental factors. In this case-control study, we evaluated the relationship between colorectal carcinoma and gene polymorphizms of CYP2C9 and CYP2C19 which are the members of CYP2C subfamily playing important roles in the metabolism of endogenous and exogenous compounds, and also assessed other possible relations with carcinogens and drugs as well as many other risk factors such as smoking, alcohol, family history of cancer and asbestos exposure. Eighty-five patients histopathologically diagnosed with colorectal carcinoma admitted to Departments of Medical Oncology and Surgery at Meram Medical Faculty and eighty-five healhty volunteers, who have no family history of cancer, were included in this study. Heterozygote and mutant genotypes of CYP2C9 and CYP2C19 genes were determined by CYP2C9*2,CYP2C9*3 and CYP2C19*2,CYP2C19*3 Mutation Detection Kits by Light Cycler Real Time Polymerase Chain Reaction. Results were statistically compared in these case-control subjects and odds ratios were used. There were no significant differences between patients with colorectal carcinoma and control groups. However, asbestos exposure ratio in patients with colorectal carcinoma was significantly higher (p < 0.05) than control subjects. Therefore, asbestos exposure may be considered as a risk factor for colorectal carcinoma.Öğe Kolorektal kanserli hastalarda sitokrom P450 (CYP2C9 ve CYP2C19) genetik polimorfizm sıklığı(2009) Büyükdoğan, Murat; Bpruban, M. Cem; Artac, Mehmet; Demirel, SennurÖzellikle gelişmiş ülkelerin önemli sağlık sorunlarından biri olan kolorektal kanserler, genetik ve çevresel faktörlerin katkılarıyla gelişen multifaktöriyel bir hastalıktır. Bu vaka kontrol çalışmasında kolorektal karsinoma ile CYP2C2 alt gurubunun bir üyesi olan endojen ve eksojen maddelerin karsinojenlerin ve ilaçların metabolizmasında önemli rol alan CYP2C9 ve CYP2C19 gen polimorfizmini ve aynı zamanda sigara, alkol, ailede kanser hikayesi, asbestoz maruziyeti gibi risk faktörlerini araştırdık. Çalışmaya ailesinde kanser hikayesi olmayan 85 sağlıklı gönüllü ile Meram Tıp Fakültesi Tıbbi Onkoloji ve Genel Cerrahi kliniklerine başvuran klinik ve histopatolojik olarak çoğunluğu adenokarsinom olan kolorektal kanserli 85 hasta alındı. CYP2C9 ve CYP2C19 genlerinin heterozigot ve mutant genotiplerini belirlemek için CYP2C9*2, CYP2C9*3 ve CYP2C19*2, CYP2C19*3 mutasyon saptama kitleri Light Cycler Real Time Polymerase Chain Reaction ile kullanıldı. Sonuçlar vaka ve kontrol guruplarında istatistiksel olarak karşılaştırıldı ve hesaplanan odds oranları kullanıldı. Kolorektal karsinomdaki risk faktörleri ve CYP2C9*2, CYP2C9*3 ve CYP2C19*2, CYP2C19*3 genlerinin polimorfik genotip sıklıklarının araştırıldığı bu vaka kontrol çalışmasında; kolorektal kanserli hastalar ve kontrol gurubu arasında anlamlı fark saptanamadı. (p 0.05). Kolorektal kanserli hastalarda beyaz toprağa maruz kalanların oranı anlamlı oranda (p 0.05) yüksek bulundu ve beyaz toprağın kolorektal kanser için bir risk faktörü olabileceği düşünüldü.Öğe METHYLATION OF SFRP2, P16, DAPK1, HIC1 AND MGMT GENES AND RELATING K-Ras GENE (CODONS 12-13) MUTATIONS WITH COLORECTAL CANCERS(JOHN WILEY & SONS INC, 2009) Pehlivan, Sacide; Artac, Mehmet; Kilicarslan, Can; Bozcuk, Hakan; Sever, Tugce; Pehlivan, Mustafa[Abstract not Available]Öğe Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer(MEDKNOW PUBLICATIONS & MEDIA PVT LTD, 2015) Mutlu, Hasan; Musri, Fatma Yalcin; Artac, Mehmet; Kargi, Aysegul; Ozdogan, Mustafa; Bozcuk, HakanBackground: We aimed to assess the efficacy of a metronomic regimen with cyclophosphamide and etoposide in heavily treated patients with metastatic breast cancer (MBC). Materials and Methods: A total of 77 patients with MBC used continuous oral cyclophosphamide 50 mg/day and oral etoposide given as 2 x 50 mg/day for 2 days per week, were analyzed retrospectively from Akdeniz University and Selcuk University. The patients with MBC are predominantly refractory to antracyclines, taxanes, and antimetabolites. Results: The patients were treated and followed between May 2005 and June 2014. The median progression-free and overall survival (PFS and OS) were 7.03 (5.06-8.99) and 32.5 (22.5-42.4) months, respectively. No prognostic factor was found for OS. Conclusions: Metronomic treatment regimen with cyclophosphamide and etoposide is a novel and effective strategy in heavily pretreated MBC patients. This regimen can be used in early or late steps as independently from prognostic factors. Moreover, it has very low toxicity and is cheap. Impressive survival data and low cost may make this regimen a highly preferable option.Öğe Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)(SPRINGER JAPAN KK, 2013) Artac, Mehmet; Bozcuk, Hakan; Kiyici, Aysel; Eren, Orhan Onder; Boruban, Melih Cem; Ozdogan, MustafaOur objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Median age was 51 years (range 28-75). Median leptin level was 19400 pg/ml (1970-91900) and estradiol level 29.6 pg/ml (4.0-181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was a parts per thousand yen19400 pg/ml (HR = 0.38; 95% CI: 0.16-0.91). This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.Öğe STRATEGIES FOR INDEPTH INVOLVEMENT OF NATIONAL ACCREDIATIALING PROGRAMS IN CANCER CARE THE TURKISH EXPERIENCE(WILEY-BLACKWELL, 2014) Turhal, Serdar; Saip, Pinar; Sahin, Berksoy; Bozcuk, Hakan; Coskun, Senol; Karabulut, Bulent; Artac, Mehmet[Abstract not Available]
